Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 35 entries
Sorted by: Best Match Show Resources per page
Soy versus whey protein bars: effects on exercise training impact on lean body mass and antioxidant status.

Nutrition journal

Brown EC, DiSilvestro RA, Babaknia A, Devor ST.
PMID: 15588291
Nutr J. 2004 Dec 08;3:22. doi: 10.1186/1475-2891-3-22.

BACKGROUND: Although soy protein may have many health benefits derived from its associated antioxidants, many male exercisers avoid soy protein. This is due partly to a popular, but untested notion that in males, soy is inferior to whey in...

Cite
Brown EC, DiSilvestro RA, Babaknia A, et al. Soy versus whey protein bars: effects on exercise training impact on lean body mass and antioxidant status. Nutr J. 2004;3:22doi: 10.1186/1475-2891-3-22.
Brown, E. C., DiSilvestro, R. A., Babaknia, A., & Devor, S. T. (2004). Soy versus whey protein bars: effects on exercise training impact on lean body mass and antioxidant status. Nutrition journal, 322. https://doi.org/10.1186/1475-2891-3-22
Brown, Erin C, et al. "Soy versus whey protein bars: effects on exercise training impact on lean body mass and antioxidant status." Nutrition journal vol. 3 (2004): 22. doi: https://doi.org/10.1186/1475-2891-3-22
Brown EC, DiSilvestro RA, Babaknia A, Devor ST. Soy versus whey protein bars: effects on exercise training impact on lean body mass and antioxidant status. Nutr J. 2004 Dec 08;3:22. doi: 10.1186/1475-2891-3-22. PMID: 15588291; PMCID: PMC539287.
Copy Download .nbib Format: NLM
Treatment of cervical intraepithelial neoplasia levels 2 and 3 with adapalene, a retinoid-related molecule.

Journal of lower genital tract disease

DiSilvestro PA, DiSilvestro JM, Lernhardt W, Pfahl M, Mannel RS.
PMID: 17043560
J Low Genit Tract Dis. 2001 Jan;5(1):33-7. doi: 10.1046/j.1526-0976.2001.51007.x.

OBJECTIVES: This study examined dose scheduling, safety, and efficacy of adapalene in the treatment of CIN2 and CIN3.METHODS: Patients were instructed on insertion and removal of an adapalene delivery system. Treatment regimens of 4, 8, and 14 days were...

Cite
DiSilvestro PA, DiSilvestro JM, Lernhardt W, et al. Treatment of cervical intraepithelial neoplasia levels 2 and 3 with adapalene, a retinoid-related molecule. J Low Genit Tract Dis. 2001;5(1):33-7doi: 10.1046/j.1526-0976.2001.51007.x.
DiSilvestro, P. A., DiSilvestro, J. M., Lernhardt, W., Pfahl, M., & Mannel, R. S. (2001). Treatment of cervical intraepithelial neoplasia levels 2 and 3 with adapalene, a retinoid-related molecule. Journal of lower genital tract disease, 5(1), 33-7. https://doi.org/10.1046/j.1526-0976.2001.51007.x
DiSilvestro, P A, et al. "Treatment of cervical intraepithelial neoplasia levels 2 and 3 with adapalene, a retinoid-related molecule." Journal of lower genital tract disease vol. 5,1 (2001): 33-7. doi: https://doi.org/10.1046/j.1526-0976.2001.51007.x
DiSilvestro PA, DiSilvestro JM, Lernhardt W, Pfahl M, Mannel RS. Treatment of cervical intraepithelial neoplasia levels 2 and 3 with adapalene, a retinoid-related molecule. J Low Genit Tract Dis. 2001 Jan;5(1):33-7. doi: 10.1046/j.1526-0976.2001.51007.x. PMID: 17043560.
Copy Download .nbib Format: NLM
Biodiversity targets will not be met without debt and tax justice.

Nature ecology & evolution

Dempsey J, Irvine-Broque A, Bigger P, Christiansen J, Muchhala B, Nelson S, Rojas-Marchini F, Shapiro-Garza E, Schuldt A, DiSilvestro A.
PMID: 34931053
Nat Ecol Evol. 2021 Dec 20; doi: 10.1038/s41559-021-01619-5. Epub 2021 Dec 20.

No abstract available.

Cite
Dempsey J, Irvine-Broque A, Bigger P, et al. Biodiversity targets will not be met without debt and tax justice. Nat Ecol Evol. 2021;doi: 10.1038/s41559-021-01619-5.
Dempsey, J., Irvine-Broque, A., Bigger, P., Christiansen, J., Muchhala, B., Nelson, S., Rojas-Marchini, F., Shapiro-Garza, E., Schuldt, A., & DiSilvestro, A. (2021). Biodiversity targets will not be met without debt and tax justice. Nature ecology & evolution, . https://doi.org/10.1038/s41559-021-01619-5
Dempsey, Jessica, et al. "Biodiversity targets will not be met without debt and tax justice." Nature ecology & evolution vol. (2021). doi: https://doi.org/10.1038/s41559-021-01619-5
Dempsey J, Irvine-Broque A, Bigger P, Christiansen J, Muchhala B, Nelson S, Rojas-Marchini F, Shapiro-Garza E, Schuldt A, DiSilvestro A. Biodiversity targets will not be met without debt and tax justice. Nat Ecol Evol. 2021 Dec 20; doi: 10.1038/s41559-021-01619-5. Epub 2021 Dec 20. PMID: 34931053.
Copy Download .nbib Format: NLM
Risk-Reducing Salpingo-Oophorectomy and Breast Cancer Risk Reduction in the Gynecologic Oncology Group Protocol-0199 (GOG-0199).

JNCI cancer spectrum

Mai PL, Miller A, Gail MH, Skates S, Lu K, Sherman ME, Ioffe OB, Rodriguez G, Cohn DE, Boggess J, Rutherford T, Kauff ND, Rader JS, Phillips KA, DiSilvestro PA, Olawaiye AB, Ridgway MR, Greene MH, Piedmonte M, Walker JL.
PMID: 32337492
JNCI Cancer Spectr. 2019 Oct 10;4(1):pkz075. doi: 10.1093/jncics/pkz075. eCollection 2020 Feb.

BACKGROUND: Risk-reducing salpingo-oophorectomy (RRSO) has been associated with approximately 50% breast cancer risk reduction among women with a pathogenic variant in METHODS: We estimated incidence rates of breast cancer and all cancers combined during 5 years of follow-up among...

Cite
Mai PL, Miller A, Gail MH, et al. Risk-Reducing Salpingo-Oophorectomy and Breast Cancer Risk Reduction in the Gynecologic Oncology Group Protocol-0199 (GOG-0199). JNCI Cancer Spectr. 2019;4(1):pkz075doi: 10.1093/jncics/pkz075.
Mai, P. L., Miller, A., Gail, M. H., Skates, S., Lu, K., Sherman, M. E., Ioffe, O. B., Rodriguez, G., Cohn, D. E., Boggess, J., Rutherford, T., Kauff, N. D., Rader, J. S., Phillips, K. A., DiSilvestro, P. A., Olawaiye, A. B., Ridgway, M. R., Greene, M. H., Piedmonte, M., & Walker, J. L. (2020). Risk-Reducing Salpingo-Oophorectomy and Breast Cancer Risk Reduction in the Gynecologic Oncology Group Protocol-0199 (GOG-0199). JNCI cancer spectrum, 4(1), pkz075. https://doi.org/10.1093/jncics/pkz075
Mai, Phuong L, et al. "Risk-Reducing Salpingo-Oophorectomy and Breast Cancer Risk Reduction in the Gynecologic Oncology Group Protocol-0199 (GOG-0199)." JNCI cancer spectrum vol. 4,1 (2020): pkz075. doi: https://doi.org/10.1093/jncics/pkz075
Mai PL, Miller A, Gail MH, Skates S, Lu K, Sherman ME, Ioffe OB, Rodriguez G, Cohn DE, Boggess J, Rutherford T, Kauff ND, Rader JS, Phillips KA, DiSilvestro PA, Olawaiye AB, Ridgway MR, Greene MH, Piedmonte M, Walker JL. Risk-Reducing Salpingo-Oophorectomy and Breast Cancer Risk Reduction in the Gynecologic Oncology Group Protocol-0199 (GOG-0199). JNCI Cancer Spectr. 2019 Oct 10;4(1):pkz075. doi: 10.1093/jncics/pkz075. eCollection 2020 Feb. PMID: 32337492; PMCID: PMC7050151.
Copy Download .nbib Format: NLM
Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial.

Gynecologic oncology

Colombo N, Moore K, Scambia G, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley WH, Kim JW, Mathews C, Liu J, Lowe ES, Bloomfield R, DiSilvestro P.
PMID: 34353615
Gynecol Oncol. 2021 Oct;163(1):41-49. doi: 10.1016/j.ygyno.2021.07.016. Epub 2021 Aug 02.

OBJECTIVES: In the phase III SOLO1 trial (NCT01844986), maintenance olaparib provided a substantial progression-free survival benefit in patients with newly diagnosed, advanced ovarian cancer and a BRCA mutation who were in response after platinum-based chemotherapy. We analyzed the timing,...

Cite
Colombo N, Moore K, Scambia G, et al. Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial. Gynecol Oncol. 2021;163(1):41-49doi: 10.1016/j.ygyno.2021.07.016.
Colombo, N., Moore, K., Scambia, G., Oaknin, A., Friedlander, M., Lisyanskaya, A., Floquet, A., Leary, A., Sonke, G. S., Gourley, C., Banerjee, S., Oza, A., González-Martín, A., Aghajanian, C., Bradley, W. H., Kim, J. W., Mathews, C., Liu, J., Lowe, E. S., Bloomfield, R., & DiSilvestro, P. (2021). Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial. Gynecologic oncology, 163(1), 41-49. https://doi.org/10.1016/j.ygyno.2021.07.016
Colombo, Nicoletta, et al. "Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial." Gynecologic oncology vol. 163,1 (2021): 41-49. doi: https://doi.org/10.1016/j.ygyno.2021.07.016
Colombo N, Moore K, Scambia G, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley WH, Kim JW, Mathews C, Liu J, Lowe ES, Bloomfield R, DiSilvestro P. Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial. Gynecol Oncol. 2021 Oct;163(1):41-49. doi: 10.1016/j.ygyno.2021.07.016. Epub 2021 Aug 02. PMID: 34353615.
Copy Download .nbib Format: NLM
Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology-Gynecologic Oncology Group Study 240 (NCT 00803062).

Molecular cancer therapeutics

Tewari KS, Sill MW, Monk BJ, Penson RT, Moore DH, Lankes HA, Ramondetta LM, Landrum LM, Randall LM, Oaknin A, Leitao MM, Eisenhauer EL, DiSilvestro P, Van Le L, Pearl ML, Burke JJ, Salani R, Richardson DL, Michael HE, Kindelberger DW, Birrer MJ.
PMID: 32847980
Mol Cancer Ther. 2020 Nov;19(11):2363-2370. doi: 10.1158/1535-7163.MCT-20-0276. Epub 2020 Aug 26.

To isolate circulating tumor cells (CTC) from women with advanced cervical cancer and estimate the impact of CTCs and treatment on overall survival and progression-free survival (PFS). A total of 7.5 mL of whole blood was drawn pre-cycle 1...

Cite
Tewari KS, Sill MW, Monk BJ, et al. Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology-Gynecologic Oncology Group Study 240 (NCT 00803062). Mol Cancer Ther. 2020;19(11):2363-2370doi: 10.1158/1535-7163.MCT-20-0276.
Tewari, K. S., Sill, M. W., Monk, B. J., Penson, R. T., Moore, D. H., Lankes, H. A., Ramondetta, L. M., Landrum, L. M., Randall, L. M., Oaknin, A., Leitao, M. M., Eisenhauer, E. L., DiSilvestro, P., Van Le, L., Pearl, M. L., Burke, J. J., Salani, R., Richardson, D. L., Michael, H. E., Kindelberger, D. W., & Birrer, M. J. (2020). Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology-Gynecologic Oncology Group Study 240 (NCT 00803062). Molecular cancer therapeutics, 19(11), 2363-2370. https://doi.org/10.1158/1535-7163.MCT-20-0276
Tewari, Krishnansu S, et al. "Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology-Gynecologic Oncology Group Study 240 (NCT 00803062)." Molecular cancer therapeutics vol. 19,11 (2020): 2363-2370. doi: https://doi.org/10.1158/1535-7163.MCT-20-0276
Tewari KS, Sill MW, Monk BJ, Penson RT, Moore DH, Lankes HA, Ramondetta LM, Landrum LM, Randall LM, Oaknin A, Leitao MM, Eisenhauer EL, DiSilvestro P, Van Le L, Pearl ML, Burke JJ, Salani R, Richardson DL, Michael HE, Kindelberger DW, Birrer MJ. Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology-Gynecologic Oncology Group Study 240 (NCT 00803062). Mol Cancer Ther. 2020 Nov;19(11):2363-2370. doi: 10.1158/1535-7163.MCT-20-0276. Epub 2020 Aug 26. PMID: 32847980; PMCID: PMC7907274.
Copy Download .nbib Format: NLM
Patient reported outcomes for cisplatin and radiation followed by carboplatin/paclitaxel versus carboplatin/paclitaxel for locally advanced endometrial carcinoma: An NRG oncology study.

Gynecologic oncology

Matulonis UA, Huang HQ, Filiaci VL, Randall M, DiSilvestro PA, Moxley KM, Fowler JM, Powell MA, Spirtos NM, Tewari KS, Richards WE, Nakayama JM, Mutch DG, Miller DS, Matei D, Wenzel LB.
PMID: 34903380
Gynecol Oncol. 2021 Dec 10; doi: 10.1016/j.ygyno.2021.11.021. Epub 2021 Dec 10.

INTRODUCTION: Chemotherapy plus radiation (Cis-RT + CP) did not demonstrate superiority in prolonging relapse-free survival compared to chemotherapy alone in patients with stage III or IVA endometrial carcinoma. The impact of treatment on quality of life (QOL), neurotoxicity (NTX)...

Cite
Matulonis UA, Huang HQ, Filiaci VL, et al. Patient reported outcomes for cisplatin and radiation followed by carboplatin/paclitaxel versus carboplatin/paclitaxel for locally advanced endometrial carcinoma: An NRG oncology study. Gynecol Oncol. 2021;doi: 10.1016/j.ygyno.2021.11.021.
Matulonis, U. A., Huang, H. Q., Filiaci, V. L., Randall, M., DiSilvestro, P. A., Moxley, K. M., Fowler, J. M., Powell, M. A., Spirtos, N. M., Tewari, K. S., Richards, W. E., Nakayama, J. M., Mutch, D. G., Miller, D. S., Matei, D., & Wenzel, L. B. (2021). Patient reported outcomes for cisplatin and radiation followed by carboplatin/paclitaxel versus carboplatin/paclitaxel for locally advanced endometrial carcinoma: An NRG oncology study. Gynecologic oncology, . https://doi.org/10.1016/j.ygyno.2021.11.021
Matulonis, Ursula A, et al. "Patient reported outcomes for cisplatin and radiation followed by carboplatin/paclitaxel versus carboplatin/paclitaxel for locally advanced endometrial carcinoma: An NRG oncology study." Gynecologic oncology vol. (2021). doi: https://doi.org/10.1016/j.ygyno.2021.11.021
Matulonis UA, Huang HQ, Filiaci VL, Randall M, DiSilvestro PA, Moxley KM, Fowler JM, Powell MA, Spirtos NM, Tewari KS, Richards WE, Nakayama JM, Mutch DG, Miller DS, Matei D, Wenzel LB. Patient reported outcomes for cisplatin and radiation followed by carboplatin/paclitaxel versus carboplatin/paclitaxel for locally advanced endometrial carcinoma: An NRG oncology study. Gynecol Oncol. 2021 Dec 10; doi: 10.1016/j.ygyno.2021.11.021. Epub 2021 Dec 10. PMID: 34903380.
Copy Download .nbib Format: NLM
Spinal Cord Stimulation via Percutaneous and Open Implantation: Systematic Review and Meta-Analysis Examining Complication Rates.

World neurosurgery

Blackburn AZ, Chang HH, DiSilvestro K, Veeramani A, McDonald C, Zhang AS, Daniels A.
PMID: 34343680
World Neurosurg. 2021 Oct;154:132-143.e1. doi: 10.1016/j.wneu.2021.07.077. Epub 2021 Jul 31.

BACKGROUND: Spinal cord stimulation (SCS) has become a successful therapeutic option for combating chronic pain and can be implanted via percutaneous or open (laminotomy/laminectomy) techniques. This study aimed to systematically review the complications that occur after SCS placement via...

Cite
Blackburn AZ, Chang HH, DiSilvestro K, et al. Spinal Cord Stimulation via Percutaneous and Open Implantation: Systematic Review and Meta-Analysis Examining Complication Rates. World Neurosurg. 2021;154:132-143.e1doi: 10.1016/j.wneu.2021.07.077.
Blackburn, A. Z., Chang, H. H., DiSilvestro, K., Veeramani, A., McDonald, C., Zhang, A. S., & Daniels, A. (2021). Spinal Cord Stimulation via Percutaneous and Open Implantation: Systematic Review and Meta-Analysis Examining Complication Rates. World neurosurgery, 154132-143.e1. https://doi.org/10.1016/j.wneu.2021.07.077
Blackburn, Amy Z, et al. "Spinal Cord Stimulation via Percutaneous and Open Implantation: Systematic Review and Meta-Analysis Examining Complication Rates." World neurosurgery vol. 154 (2021): 132-143.e1. doi: https://doi.org/10.1016/j.wneu.2021.07.077
Blackburn AZ, Chang HH, DiSilvestro K, Veeramani A, McDonald C, Zhang AS, Daniels A. Spinal Cord Stimulation via Percutaneous and Open Implantation: Systematic Review and Meta-Analysis Examining Complication Rates. World Neurosurg. 2021 Oct;154:132-143.e1. doi: 10.1016/j.wneu.2021.07.077. Epub 2021 Jul 31. PMID: 34343680.
Copy Download .nbib Format: NLM
Septin-2 is overexpressed in epithelial ovarian cancer and mediates proliferation via regulation of cellular metabolic proteins.

Oncotarget

James NE, Cantillo E, Yano N, Chichester CO, DiSilvestro PA, Hovanesian V, Rao RSP, Kim KK, Moore RG, Ahsan N, Ribeiro JR.
PMID: 31105878
Oncotarget. 2019 Apr 26;10(31):2959-2972. doi: 10.18632/oncotarget.26836. eCollection 2019 Apr 26.

Epithelial Ovarian Cancer (EOC) is associated with dismal survival rates due to the fact that patients are frequently diagnosed at an advanced stage and eventually become resistant to traditional chemotherapeutics. Hence, there is a crucial need for new and...

Cite
James NE, Cantillo E, Yano N, et al. Septin-2 is overexpressed in epithelial ovarian cancer and mediates proliferation via regulation of cellular metabolic proteins. Oncotarget. 2019;10(31):2959-2972doi: 10.18632/oncotarget.26836.
James, N. E., Cantillo, E., Yano, N., Chichester, C. O., DiSilvestro, P. A., Hovanesian, V., Rao, R. S. P., Kim, K. K., Moore, R. G., Ahsan, N., & Ribeiro, J. R. (2019). Septin-2 is overexpressed in epithelial ovarian cancer and mediates proliferation via regulation of cellular metabolic proteins. Oncotarget, 10(31), 2959-2972. https://doi.org/10.18632/oncotarget.26836
James, Nicole E, et al. "Septin-2 is overexpressed in epithelial ovarian cancer and mediates proliferation via regulation of cellular metabolic proteins." Oncotarget vol. 10,31 (2019): 2959-2972. doi: https://doi.org/10.18632/oncotarget.26836
James NE, Cantillo E, Yano N, Chichester CO, DiSilvestro PA, Hovanesian V, Rao RSP, Kim KK, Moore RG, Ahsan N, Ribeiro JR. Septin-2 is overexpressed in epithelial ovarian cancer and mediates proliferation via regulation of cellular metabolic proteins. Oncotarget. 2019 Apr 26;10(31):2959-2972. doi: 10.18632/oncotarget.26836. eCollection 2019 Apr 26. PMID: 31105878; PMCID: PMC6508204.
Copy Download .nbib Format: NLM
Reply to S. Gulia et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

DiSilvestro P, Lowe ES, Bloomfield R.
PMID: 33326256
J Clin Oncol. 2021 Jan 20;39(3):256. doi: 10.1200/JCO.20.03081. Epub 2020 Dec 16.

No abstract available.

Cite
DiSilvestro P, Lowe ES, Bloomfield R. Reply to S. Gulia et al. J Clin Oncol. 2020;39(3):256doi: 10.1200/JCO.20.03081.
DiSilvestro, P., Lowe, E. S., & Bloomfield, R. (2021). Reply to S. Gulia et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(3), 256. https://doi.org/10.1200/JCO.20.03081
DiSilvestro, Paul, et al. "Reply to S. Gulia et al." Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 39,3 (2021): 256. doi: https://doi.org/10.1200/JCO.20.03081
DiSilvestro P, Lowe ES, Bloomfield R. Reply to S. Gulia et al. J Clin Oncol. 2021 Jan 20;39(3):256. doi: 10.1200/JCO.20.03081. Epub 2020 Dec 16. PMID: 33326256.
Copy Download .nbib Format: NLM
The Perfect Combination: Enhancing Patient Response to PD-1-Based Therapies in Epithelial Ovarian Cancer.

Cancers

James NE, Woodman M, DiSilvestro PA, Ribeiro JR.
PMID: 32756436
Cancers (Basel). 2020 Aug 03;12(8). doi: 10.3390/cancers12082150.

Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy, with an overall 5-year survival of only 47%. As the development of novel targeted therapies is drastically necessary in order to improve patient survival, current EOC clinical trials have...

Cite
James NE, Woodman M, DiSilvestro PA, et al. The Perfect Combination: Enhancing Patient Response to PD-1-Based Therapies in Epithelial Ovarian Cancer. Cancers (Basel). 2020;12(8)doi: 10.3390/cancers12082150.
James, N. E., Woodman, M., DiSilvestro, P. A., & Ribeiro, J. R. (2020). The Perfect Combination: Enhancing Patient Response to PD-1-Based Therapies in Epithelial Ovarian Cancer. Cancers, 12(8), . https://doi.org/10.3390/cancers12082150
James, Nicole E, et al. "The Perfect Combination: Enhancing Patient Response to PD-1-Based Therapies in Epithelial Ovarian Cancer." Cancers vol. 12,8 (2020). doi: https://doi.org/10.3390/cancers12082150
James NE, Woodman M, DiSilvestro PA, Ribeiro JR. The Perfect Combination: Enhancing Patient Response to PD-1-Based Therapies in Epithelial Ovarian Cancer. Cancers (Basel). 2020 Aug 03;12(8). doi: 10.3390/cancers12082150. PMID: 32756436; PMCID: PMC7466102.
Copy Download .nbib Format: NLM
COL1A1-PDGFB fusion uterine sarcoma and its response to Imatinib therapy.

Gynecologic oncology reports

Grindstaff SL, DiSilvestro P, Quddus MR.
PMID: 33364286
Gynecol Oncol Rep. 2020 Sep 25;34:100653. doi: 10.1016/j.gore.2020.100653. eCollection 2020 Nov.

No abstract available.

Cite
Grindstaff SL, DiSilvestro P, Quddus MR. COL1A1-PDGFB fusion uterine sarcoma and its response to Imatinib therapy. Gynecol Oncol Rep. 2020;34:100653doi: 10.1016/j.gore.2020.100653.
Grindstaff, S. L., DiSilvestro, P., & Quddus, M. R. (2020). COL1A1-PDGFB fusion uterine sarcoma and its response to Imatinib therapy. Gynecologic oncology reports, 34100653. https://doi.org/10.1016/j.gore.2020.100653
Grindstaff, Samuel L, et al. "COL1A1-PDGFB fusion uterine sarcoma and its response to Imatinib therapy." Gynecologic oncology reports vol. 34 (2020): 100653. doi: https://doi.org/10.1016/j.gore.2020.100653
Grindstaff SL, DiSilvestro P, Quddus MR. COL1A1-PDGFB fusion uterine sarcoma and its response to Imatinib therapy. Gynecol Oncol Rep. 2020 Sep 25;34:100653. doi: 10.1016/j.gore.2020.100653. eCollection 2020 Nov. PMID: 33364286; PMCID: PMC7752748.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 35 entries